Trial Profile
Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo Following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application Under Non-occlusive Condition in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Tapinarof (Primary)
- Indications Atopic dermatitis; Plaque psoriasis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 04 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 24 Dec 2015 New trial record